Pfizer Inc at Wolfe Research Healthcare Conference (Virtual) Transcript
Okay. Good morning. Thanks for joining us. I'm Tim Anderson, the large-cap pharma and large-cap biotech analyst at Wolfe Research. And for the next 45 minutes, we'll be talking with Pfizer's Angela Hwang, who is President of Pfizer's Biopharmaceutical business, which is basically the entire business now. She's been in this role for about the last 2 years, but she's been with Pfizer for 23 years working across lots of geographies and therapeutic areas and business functions. So thank you, Angela, for joining us.
Questions & Answers
We're going to just jump into questions here. I thought maybe we could start with the Upjohn separation. So it officially occurred just this week. Viatris began trading, I think it was yesterday. You ran that division at one point back when it was called Essential Health. Now it was called Upjohn, and now it's part of Viatris. What will finally splitting that out allow the remaining Pfizer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
